Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin.
暂无分享,去创建一个
[1] R. Gurny,et al. Cell interaction studies of PLA-MePEG nanoparticles. , 2003, International journal of pharmaceutics.
[2] Richard B Greenwald,et al. Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.
[3] Y. Sugiyama,et al. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[4] K. Avgoustakis,et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.
[5] J. Lee,et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Bally,et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.
[7] N. Tsuda,et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). , 2000, Cancer research.
[8] Y. Machida,et al. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[9] J. Feijen,et al. Cellular Uptake of PEO Surface-Modified Nanoparticles: Evaluation of Nanoparticles Made of PLA: PEO Diblock and Triblock Copolymers , 2000, Journal of drug targeting.
[10] Y. Cai,et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[11] S. Hirota,et al. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. , 1998, Cancer letters.
[12] Y. Ikada,et al. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[13] Lawrence Mayer,et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel , 1997, Anti-cancer drugs.
[14] Martyn C. Davies,et al. In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers , 1997 .
[15] A. Kurihara,et al. Enhanced Tumor Delivery and Antitumor Activity of Palmitoyl Rhizoxin Using Stable Lipid Emulsions in Mice , 1996, Pharmaceutical Research.
[16] J. M. Shaw,et al. Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.
[17] K. Maruyama,et al. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol) , 1995 .
[18] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.
[19] N. Saijo,et al. A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[20] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[21] M. Iigo,et al. Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11 , 1993, Japanese journal of cancer research : Gann.
[22] M. Woodle,et al. Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[23] H. Kuga,et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.
[24] T. Okano,et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.
[25] B. Giovanella,et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. , 1991, Cancer research.
[26] T. Yokokura,et al. Nonlinear pharmacokinetics of CPT-11 in rats. , 1990, Cancer research.
[27] T. Furuta,et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.
[28] L. Liu,et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.
[29] M. Hashida,et al. Disposition and Tumor Localization of Mitomycin C–Dextran Conjugates in Mice , 1987, Pharmaceutical Research.
[30] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[31] U Schaeppi,et al. Toxicity of camptothecin (NSC-100880). , 1974, Cancer chemotherapy reports. Part 3.
[32] Muggia Fm,et al. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. , 1972 .
[33] H. Hansen,et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.
[34] R. Adamson,et al. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. , 1971, Journal of the National Cancer Institute.
[35] A. Guarino,et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.
[36] A. McPhail,et al. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .
[37] T. Tsuruo,et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.
[38] Rakesh K. Jain,et al. Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.
[39] A. Tolcher,et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Y. Machida,et al. Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). , 2003, Biological & pharmaceutical bulletin.
[41] P. Legrand,et al. Interactions between a macrophage cell line (J774A1) and surface-modified poly (D,L-lactide) nanocapsules bearing poly(ethylene glycol). , 1999, Journal of drug targeting.
[42] Y. Machida,et al. Antitumour characteristics of irinotecan-containing microspheres of poly-d, l-lactic acid or poly(d, l-lactic acid-co-glycolic acid) copolymers , 1998 .
[43] T Nakagawa,et al. A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.